Variables (N, %) | Worst Group (<1 y) | Control Group (1–3 y) | Best Group (>3 y) | p-value |
---|---|---|---|---|
Age (years) | 60.5 ± 10.7 | 57.1 ± 11.5 | 56.3 ± 10.3 | 0.136 |
Gender (Male/Female) | 50/17 (74.6/25.4) | 45/7 (86.5/13.5) | 22/5 (81.5/18.5) | 0.266 |
Body mass index (kg/m2) | 22.9 ± 2.8 | 23.7 ± 2.5 | 24.3 ± 2.9 | 0.096 |
MSKCC criteria | 59 (88.1) | 43 (100) | 19 (73.1) | <0.001 |
 Favorable risk | 0 | 4 (9.3) | 10 (52.6) |  |
 Intermediate risk | 39 (66.1) | 34 (79.1) | 9 (47.4) |  |
 Poor risk | 20(33.9) | 5 (11.6) | 0 |  |
Heng criteria | 64 (95.5) | 44 (84.6) | 22 (81.5) | <0.001 |
 Favorable risk | 2 (3.1) | 9(20.5) | 11 (50.0) |  |
 Intermediate risk | 46 (71.9) | 32 (72.7) | 11 (50.0) |  |
 Poor risk | 16 (25.0) | 3 (6.8) | 0 |  |
ECOG 0 | 61(93.8) | 47 (100) | 23(100) | 0.109 |
1 | 4 (6.2) | 0 | 0 | Â |
Metastatic site | Â | Â | Â | Â |
 Lung | 54 (81.8) | 42(84.0 | 23 (88.5) | 0.738 |
 Liver | 18(27.3) | 6 (12.2) | 1 (4.3) | 0.020 |
 Lymph node | 33 (49.3) | 17 (36.2) | 8 (33.3) | 0.064 |
 Bone | 23 (34.8) | 16 (34.0) | 6 (25.0) | 0.612 |
 Brain | 9 (13.6) | 5 (10.6) | 2 (8.3) | 0.758 |
 Other metastasis | 18 (27.3) | 5 (10.6) | 4 (16.7) | 0.083 |
Nephrectomy Embolization | 23(34.3) 4 (5.9) | 32 (61.5) 1 (1.9) | 24 (88.9) 3(11.1) | <0.0010.146 |
Clinical T stage | 43 (64.2) | 35 (67.3) | Â | 0.179 |
 T1 | 4 (10.8) | 6 (17.2) | 3 (18.8) |  |
 T2 | 3 (8.1) | 8(20.0) | 7 (12.5) |  |
 T3 | 15 (40.5) | 11 (31.5) | 9 (31.3) |  |
 T4 | 8 (21.6) | 3 (8.6) | 0 (18.8) |  |
 Tx | 7 (18.9) | 7 (20.0) | 2(18.8) |  |
 N1 | 13 (31.0) | 6 (14.6) | 5 (29.4) | 0.229 |
Synchronous metastasis | 58(87.9) | 31 (60.8) | 8 (30.8) | 0.001 |
Fuhrman nuclear grade | 41 (61.2) | 39 (75.0) | 22 (81.5) | 0.460 |
 1–2 | 13 (31.7) | 12 (30.8) | 10 (45.5) | |
 3–5 | 28 (68.3) | 27 (69.2) | 12 (54.5) | |
Histology | 63 (94.0) | 50 (96.2) | 26 (96.3) | 0.581 |
 Clear cell type | 50 (79.4) | 44 (89.8) | 17 (70.8) | |
 Non-clear cell type | 2 (3.2) | 1 (2.0) | 0 | |
 Chromophobe with clear cell | 2 (3.0) | 2 (3.8) | 2 (7.4) | |
 Papillary with clear cell | 7 (6.5) | 1 (2.3) | 3 (5.1) | |
 Unknown type | 2 (3.2) | 1 (2.0) | 2 (8.3) | |
Sarcomatoid presence | 3 (4.8 | 1 (2.0) | 2(8.3) | 0.168 |
 Treatment |  |  |  | 0.430 |
 Sunitinib | 42 (62.7) | 37 (71.2) | 22(81.5) |  |
 Sorafenib | 9 (13.4) | 6 (11.5) | 2 (7.4) |  |
 Pazopanib | 13 (19.4) | 9 (17.3) | 3 (11.1) |  |
 Temsirolimus | 3 (4.5) | 0 | 0 |  |
RECIST response | Â | Â | Â | <0.001 |
 CR | 0 | 4 (9.1) | 3 (15.0) |  |
 PR | 9 (20.0) | 19 (43.2) | 9 (45.0) |  |
 SD | 11 (24.4) | 14 (31.8) | 8 (40.0) |  |
 PD | 25 (55.6) | 7 (15.9) | 0 |  |
Laboratory findings | Â | Â | Â | Â |
 Leukocytosis/Leucopenia | 19/1 (28.4/1.6) | 4/2 (8.9/4.4) | 2/1(7.4/3.7) | 0.030 |
 Anemia | 51 (76.4) | 17 (37.8) | 8 (29.6) | <0.001 |
 Thrombocytosis/penia | 14/2(20.9/3.0) | 4/2 (8.9/4.4) | 0/0 | 0.041 |
 Neutrophilia/penia | 18/0 (26.9/0) | 2/1 (4.4/2.2) | 2/1(7.4/3.7) | 0.002 |
 Lymphocytosis/penia | 1/37 (1.5/55.2) | 4/4 (8.9/8.9) | 3/1 (11.1/3.7) | <0.001 |
 Hyper/hypocalcemia | 5/11 (7.4/16.4) | 1/2 (2.2/4.4) | 0/1 (0/3.7) | 0.077 |
 Hypoalbuminemia | 12(17.9) | 0 | 0 | 0.002 |
 LDH elevated | 10 (14.9) | 2(4.4) | 0 | 0.051 |
 Neutrophil percent high/low | 16/1 (23.9/1.5) | 0/8(0/17.8) | 1/6 (3.7/22.2) | <0.001 |
PFS (mo.) | 2.7 (1–9.3) | 9.5 (1–28.3) | 12.2 (1–68.4) | <0.001 |
OS (mo.) | 5.5 (0.3–11.6) | 21.6 (12.1–35.7) | 63.1 (36.6–88.4) | <0.001 |